famotidine (redirected from Mylanta AR)

famotidine /fam·o·ti·dine/ (fam-o´tĭ-dēn) a histamine H2 receptor antagonist, which inhibits gastric acid secretion; used in the treatment and prophylaxis of gastric or duodenal ulcers, gastroesophageal reflux disease, upper gastrointestinal bleeding, and conditions associated with gastric hypersecretion.

---

fa·mo·ti·dine (f-mt-dn)

n.

A histamine H₂ antagonist used in the treatment of duodenal ulcers.

---

famotidine

[famot′idēn]

an oral and parenteral antiulcer drug; an H₂-receptor antagonist.

indications It is prescribed in treatment of duodenal ulcer and pathologic hypersecretory conditions, and for stress-ulcer prophylaxis.

contraindications Famotidine should be used with caution in patients with impaired kidney function.

adverse effects Among adverse effects reported are headache, dizziness, constipation, diarrhea, and temporary irritation of the injection site.

---

famotidine [fam-o´tĭ-dēn]

an antagonist of histamine H₂receptors, inhibiting the action of histamine at cell surface receptors of the gastric parietal cells and reducing basal gastric acid secretion and secretion stimulated by food, histamine, gastrin, caffeine, and insulin. It is administered orally for the short-term (two months) treatment and, at reduced dosage, the long term prevention, of peptic ulcers, for the relief of symptoms associated with hyperacidity, such as heartburn and acid indigestion, and for the treatment of gastroesophageal reflux disease, upper gastrointestinal bleeding, and pathological hypersecretory conditions such as zollinger-ellison syndrome.

---

famotidine

(fmō´tdēn´),
n brand names: Pepcid, Pepcid IV;
drug class: H₂-histamine receptor antagonist;
action: inhibits histamine at H₂ receptor site in parietal cells, which inhibits gastric acid secretion;
uses: short-term treatment of active duodenal ulcer, gastric ulcer, and heartburn.

---

famotidine

a histamine H₂-receptor antagonist, similar to cimetidine.

---

famotidine

Apo-Famotidine (CA), Gen-Famotidine (CA), Mylanta AR, Novo-Famotidine (CA), Nu-Famotidine (CA), Pepcid, Pepcid AC, Ulcidine (CA), Ultra Heartburn Relief (UK)

Pharmacologic class: Histamine₂-receptor antagonist

Therapeutic class: Antiulcer drug

Pregnancy risk category B

Action

Blocks action of histamine at histamine₂-receptor sites in gastric parietal cells, inhibiting gastric acid secretion and stabilizing pepsin

Availability

Gelcaps: 10 mg

Oral suspension: 40 mg/5 ml

Solution for injection: 10 mg/ml, 20 mg/50 ml of normal saline solution

Tablets: 10 mg, 20 mg, 40 mg

Tablets (chewable): 10 mg

Tablets (orally disintegrating): 20 mg, 40 mg

⊘Indications and dosages

➣ Active duodenal ulcers and benign gastric ulcers

Adults: 40 mg P.O. once daily at bedtime or 20 mg P.O. b.i.d. for up to 8 weeks

➣ Prophylaxis of duodenal ulcers

Adults: 20 mg P.O. once daily at bedtime

➣ Gastroesophageal reflux disease

Adults: 20 mg P.O. b.i.d. for up to 6 weeks. Maximum dosage is 40 mg b.i.d. for up to 12 weeks.

Children ages 1 to 16: 1 mg/kg P.O. daily in two divided doses, to a maximum of 40 mg b.i.d.

➣ Gastric hypersecretory conditions (such as Zollinger-Ellison syndrome)

Adults: Initially, 20 mg P.O. q 6 hours, increased as needed to 160 mg q 6 hours

➣ Hospitalized patients with pathologic hypersecretory conditions or ulcers; patients who can't take oral drugs

Adults: 20 mg I.V. q 12 hours

➣ Prevention or treatment of heartburn, acid indigestion, and sour stomach (Pepcid AC only)

Adults: For prevention, 10 mg P.O. 1 hour before eating, or 10-mg chewable tablet 15 minutes before eating, to a maximum of 20 mg/24 hours for up to 2 weeks. For symptomatic treatment, 10 mg P.O. once or twice daily.

Dosage adjustment

• Renal impairment

Contraindications

• Hypersensitivity to drug or other histamine₂-receptor antagonists
• Alcohol intolerance (some oral liquid products)

Precautions

Use cautiously in:
• renal impairment
• elderly patients
• pregnant or breastfeeding patients.

Administration

• Be aware that drug usually is given in one daily dose to patients with renal insufficiency.
• Give P.O. form with foods or liquids.
• Dilute I.V. form with 10 ml dextrose 5% in water or normal saline solution (100 ml) for I.V. piggyback administration.
• Deliver by I.V. push over 2 minutes or intermittent infusion over 30 minutes.
• Know that drug may cause transient irritation at I.V. site.

Route	Onset	Peak	Duration
P.O.	Within 1 hr	1-4 hr	6-12 hr
I.V.	Rapid	0.5-3 hr	8-15 hr

Adverse reactions

CNS: dizziness, headache, paresthesia, asthenia

CV: palpitations

GI: nausea, diarrhea, constipation, dry mouth, anorexia

EENT: orbital edema, conjunctival redness, tinnitus

Musculoskeletal: musculoskeletal pain

Skin: flushing, acne, dry skin

Other: altered taste, fever, pain at injection site, hypersensitivity reactions

Interactions

Drug-food. Caffeine-containing foods: increased gastric irritation

Drug-herbs. Yerba maté: decreased famotidine clearance

Drug-behaviors. Alcohol use, smoking: increased gastric irritation

Patient monitoring

• Assess patient for GI signs and symptoms.
• Monitor blood urea nitrogen and creatinine levels in patients with renal impairment.

Patient teaching

• Tell patient that drug is most effective when taken at bedtime.
• Inform patient that pain relief may not begin until several days after therapy starts.
• Caution patient to avoid alcohol, caffeine, and smoking because they may increase gastric irritation.
• Tell female patient to inform prescriber if she is pregnant or breastfeeding.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the foods, herbs, and behaviors mentioned above.

---

famotidine

Pepcid^™ Therapeutics An agent used to treat peptic ulcer disease by blocking binding of histamine to H₂ receptors, resulting in ↓ intracellular concentration of cAMP and acid secretion by gastric parietal cells Adverse reactions Diarrhea, headache, drowsiness, fatigue, muscle pain, constipation, rarely, also mental confusion, agranulocytosis, gynecomastia, impotence, allergic reactions, myalgias, tachycardia, arrhythmias, interstitial nephritis, etc. See Histamine receptor antagonist.